Fibromyalgia Treatment Market, (By Drug Class: Antidepressants, Antiepileptics, Muscle Relaxants, Analgesics, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Mar 2024

Code : CMI1691

Pages :176

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Concentration and Competitive Landscape

Fibromyalgia Treatment Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Approval and launch of novel fibromyalgia treatment drugs

Increasing approval and launch of novel fibromyalgia treatment are expected to drive the market growth over the forecast period. For instance, in May, 2022, Scilex Holding Company, a biopharmaceutical company, committed to develop SP-104 for fibromyalgia treatment. SP-104 is a novel, proprietary, fixed dose, delayed burst release of low dose naltrexone hydrochloride, 4.5 mg, for the treatment of fibromyalgia. Phase 1 clinical trial data showed that SP-104 treated healthy volunteers and had lower rates of adverse events, as compared with immediate release naltrexone -treated volunteers.

Key Players Insights